Angéla Virone-Oddos
0000-0002-4511-0612
Publication & Citation Trends
Publications
0 total
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile OA
Cited by 22
Semantic Scholar
Abstract 2727: Pre-clinical development of a novel anti-GPRC5D inducing potent anti-tumor effect through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for multiple myeloma
Cited by 0
Semantic Scholar
Abstract 5277: The ROCK-2 inhibitor belumosudil exerts a direct antimyeloma effect and improves isatuximab-mediated cytotoxicity against multiple myeloma cells
Cited by 1
Semantic Scholar
The Combination of the Novel Trifunctional BCMA NK Cell Engager SAR445514 with IMiDs and Celmods Enhances Cytotoxicity Against Multiple Myeloma Cells As Compared to Single Agents
Cited by 2
Semantic Scholar
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 OA
Cited by 79
Semantic Scholar
Inhibition of Rho-Associated Coiled-Coil Containing Protein Kinases with Belumosudil Mesylate Shows Anti-Tumor and Immune Modulatory Properties in Models of Multiple Myeloma OA
Cited by 2
Semantic Scholar
Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML
Cited by 2
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(16)
CAR-T cell therapy research
(12)
Multiple Myeloma Research and Treatments
(9)
Immune Cell Function and Interaction
(9)
Chronic Lymphocytic Leukemia Research
(7)
Affiliations
Sanofi (France)
Sanofi (United States)
French Norwegian Foundation